Cyfuse Biomedical
Cyfuse Biomedical is a Tokyo-based clinical-stage Japanese biotech that develops scaffold-free 3D bioprinting systems and cell-based products for regenerative medicine and drug discovery, serving pharmaceutical companies, hospitals, and research institutions via its proprietary Kenzan Method platform.
- Company typePublic
- Founded2010
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cyfuse Biomedical does
Cyfuse Biomedical K.K. is a Japanese clinical-stage biotechnology company that develops and commercializes scaffold-free 3D bioprinting systems and cell-based products for regenerative medicine and drug discovery. Founded in 2010 and headquartered in Tokyo with an additional Fukuoka office, the company went public on the Tokyo Stock Exchange Growth Market in December 2022 (ticker: 4892) and added a secondary listing on the Fukuoka Stock Exchange Q-Board in December 2025. The company operates with 11–50 employees and an enterprise-focused go-to-market combining direct sales with channel partnerships.
The company's core technology is the proprietary Kenzan Method, a scaffold-free bioprinting approach in which cell spheroids are fixed on a needle array and stacked into three-dimensional tissues without scaffolds or exogenous materials. This platform underpins the S-PIKE bio-3D printer (the flagship hardware product), the Human 3D Mini Liver drug discovery evaluation tool (with a Disease Model line launched in December 2025), the newly developed 3D Mini Intestine Model (announced November 2025), and a pipeline of 3D Cell Products—including cell-made artificial blood vessels and 3D nerve conduits—currently in clinical trials at Saga University and Kyoto University. The Kenzan Method and S-PIKE are registered trademarks; supporting patents and clinical regulatory pathways create a defensible position in a niche field.
Cyfuse generates revenue through three streams: hardware sales of the S-PIKE bio-3D printer (distributed in Japan by Sysmex Corporation and globally by Marubeni Corporation), product sales of drug discovery tools including the Human 3D Mini Liver family, and pre-commercial regenerative medicine products expected to reach commercialization via licensing/royalty economics. The customer base is concentrated in pharmaceutical and biotech companies (for drug discovery tools), hospitals and academic medical centers (for clinical-stage regenerative medicine products), and research institutions. The company has built a deep partnership ecosystem with major Japanese corporates—Taiyo Holdings (manufacturing), Hitachi Global Life Solutions (modular CPC), Iwatani, Fujimori/Zacros, NSK, Medipal Holdings, Kuraray, and PHC Corporation—covering manufacturing scale-up, automation, materials, and distribution. Pricing is quote-based and not publicly disclosed.
Cyfuse Biomedical firmographics
Firmographics- Name
- Cyfuse Biomedical
- Legal name
- 株式会社サイフューズ
- Website
- https://cyfusebio.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cyfuse Biomedical is a Tokyo-based clinical-stage Japanese biotech that develops scaffold-free 3D bioprinting systems and cell-based products for regenerative medicine and drug discovery, serving pharmaceutical companies, hospitals, and research institutions via its proprietary Kenzan Method platform.
- Ownership category
- akta.pro rank
Cyfuse Biomedical industry classification
Industry- Product category
- 3D Bioprinting and Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industries
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
Keywords
Where Cyfuse Biomedical is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Cyfuse Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Bio-3D Printer Sales: Sale of S-PIKE bio-3D printer systems to research institutions, pharmaceutical companies, and healthcare facilities
- Drug Discovery Support Tools: Sales of Human 3D Mini-Liver products and services for pharmaceutical drug discovery and toxicity evaluation
- Regenerative Medicine Products: Development and potential commercialization of 3D cell products for regenerative medicine applications including artificial blood vessels and nerve conduits
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Cyfuse Biomedical product offering
Product offeringCore offering
Cyfuse Biomedical develops scaffold-free 3D bioprinting systems using its proprietary Kenzan Method to construct three-dimensional tissues from cell spheroids without scaffolds. Its core commercial offerings are the S-PIKE bio-3D printer (hardware), drug discovery support tools such as the Human 3D Mini Liver, and a pipeline of 3D cell products (artificial blood vessels, nerve conduits) for regenerative medicine applications.
Product overview
Cyfuse Biomedical operates as a bio 3D printing platform company offering both hardware and biological products. The core offering consists of the S-PIKE® bio 3D printer, which uses a unique needle-array system to stack cell spheroids into three-dimensional tissues without scaffold materials. Complementing the hardware are biological products including the Human 3D Mini Liver (a drug discovery evaluation tool) and a pipeline of 3D Cell Products (100% cell-derived tissues and organs such as artificial blood vessels and nerve conduits) targeting regenerative medicine applications. A new compact dispensing machine (CAP) was launched in 2026. The portfolio is unified by the company's scaffold-free spheroid-based bioprinting platform technology, which serves both the drug discovery tools segment and the regenerative medicine products segment.
Differentiator
Problem solved
Functional benefit
Brands
- Cyfuse: Company brand name used internationally; Japanese name is 株式会社サイフューズ (Cyfuse Biomedical K.K.)
Products and services
- S-PIKE® (スパイク) Bio 3D Printing System Flagship bio-3D printer that arrays and fixes spheroids on a single needle and aligns those needles to construct three-dimensional tissues and organs. Sold to pharmaceutical companies, research institutions, and healthcare facilities for regenerative medicine and drug discovery research.
- Human 3D Mini Liver (ヒト3Dミニ肝臓) A scaffold-free 3D bio-printed human liver tissue that reproduces human liver function as an innovative in vitro evaluation model. Used by pharmaceutical companies for drug toxicity screening, metabolic function assessment, and disease-specific modeling.
- 3D Cell Products (3D細胞製品) Tissues and organs manufactured from 100% cells using the company's bio-3D printing platform. Includes cell-based artificial blood vessels, three-dimensional nerve conduits, and other regenerative medicine products intended for clinical applications in hospitals and medical institutions.
- 3D Mini Intestine Model (3Dミニ腸管モデル) A 3D mini intestine model expanding Cyfuse's organoid and tissue model portfolio for pharmaceutical drug discovery and preclinical evaluation applications.
- CAP (折りたたみ式コンパクト型分注機) - Folding Compact Dispensing Machine A folding compact dispensing machine used for precision liquid handling in cell and tissue preparation workflows supporting bioprinting operations.
Quantifiable outcome
- World's first clinical trial for cell-made artificial blood vessels using patient's own cells
- +1 more outcomes
Companies that use Cyfuse Biomedical
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Cyfuse Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cyfuse Biomedical partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, regional and core.
- NSK Ltd. (Nippon Seiki)majorJoint development of new bio-3D printer for commercial production of regenerative medicine and 3D cell products.
- Kuraray Co., Ltd.majorBasic agreement for business and capital partnership in regenerative medicine and cell therapy field.
- PHC CorporationmajorPHC Corporation and Cyfuse Biomedical announced advanced production technology for regenerative and cell therapy applications in March 2025
- NSK Ltd. (Nippon Seiki)majorCollaboration for new technology development in regenerative and cell therapy field. Joint development for factory automation, system integration, and digital transformation for next-generation manufacturing.
- Fukuoka Jisho CorporationregionalBusiness and capital partnership for regional revitalization through biotech medical community in Kyushu/Fukuoka area.
- Medipal Holdings CorporationmajorDevelopment investment agreement for practical application of regenerative medicine products. Medipal provides distribution network and pharmaceutical logistics expertise.
- Fujimori Corporation (Zacros)majorBusiness and capital partnership for regenerative and cell therapy field. Joint technology development for mass cell culture technology and cell product commercialization.
- Hitachi Global Life Solutions, Inc.majorCo-developed next-generation module type Cell Processing Center (CPC) for manufacturing cell products. Partnership for establishing new manufacturing equipment models.
- Iwatani CorporationmajorBusiness and capital partnership for practical application of 3D cell products. Iwatani provides infrastructure supplier expertise for commercialization.
- Marubeni CorporationcoreGlobal expansion partnership for S-PIKE bio-3D printer worldwide distribution. Marubeni supports international sales and market development.
- Taiyo Holdings Co., Ltd.coreComprehensive partnership for accelerating product manufacturing in regenerative and cell therapy field. Taiyo Pharmatech operates manufacturing facility with next-generation module CPC developed with Hitachi Global Life Solutions.
- Sysmex CorporationcoreSales partnership for S-PIKE bio-3D printer distribution in Japan market. Sysmex serves as primary sales partner for the bio-3D printer products.
- Sekisui Chemical Co., Ltd.majorBusiness partnership for expanding drug discovery support services. Collaboration with Sekisui Medical for practical application of 3D structures for drug discovery.
Scale indicators4 records
Recent moves10 records
Expansion highlights6 records
Cyfuse Biomedical competitors and assessment
Company assessmentDirect peers
- CELLINK (BICO Group): Global leader in 3D bioprinting hardware, bioinks, and lab automation. Directly competes with Cyfuse's S-PIKE printer platform and offers comparable scaffold-based bioprinting consumables to research and pharma customers worldwide.
- Organovo: US-based pioneer in 3D bioprinted human tissues, with focus on liver and intestinal tissue models for drug discovery and disease modeling. Comparable in product category (3D tissue products for pharma R&D) though scaffold-based rather than scaffold-free.
- Aspect Biosystems: Canada-based bioprinting company developing tissue therapeutics using proprietary microfluidic 3D bioprinting platform. Directly comparable as a tissue-engineering platform targeting regenerative medicine applications with bioprinted tissue products.
- Poietis: France-based 3D bioprinting company with laser-assisted bioprinting technology for tissue engineering and regenerative medicine. Comparable as a bioprinting platform player serving pharma research and cell therapy development.
- InSphero: Switzerland-based 3D cell culture company producing organoid models (liver, islet, tumor) for drug discovery and toxicology. Directly comparable to Cyfuse's 3D Mini Liver drug-discovery tool offering.
- Emulate: US-based organ-on-chip platform company whose liver-chip and intestine-chip compete with Cyfuse's 3D Mini Liver and 3D Mini Intestine for pharma in vitro evaluation budgets.
Broad incumbents
- Fujifilm: Japanese conglomerate with a significant regenerative medicine and cell therapy business (CDMO, iPSC-derived products). An external director of Cyfuse is a former Fujifilm life sciences executive, indicating deep industry overlap.
- 3D Systems: US-based broad 3D printing incumbent with a healthcare/bioprinting division (including the Allevi bioprinter line). Competes broadly in medical and dental 3D printing applications adjacent to Cyfuse's healthcare focus.
Regional players
- Healios K.K. Japanese clinical-stage cell therapy company developing stem cell treatments for regenerative medicine indications. Comparable as a Japan-domiciled regenerative medicine company advancing cell-based therapies through clinical trials.
Emerging players
- Regemat 3D: Spain-based emerging player in 3D bioprinting hardware and bioinks focused on personalized regenerative medicine. Comparable as a niche bioprinting platform targeting clinical and research applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cyfuse Biomedical social profiles
Digital presenceCyfuse Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyfuse Biomedical leadership team
Management profileNumber of profiles
Profiles9 records
Cyfuse Biomedical funding detail
Funding detailFunding overview
Funding rounds8 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyfuse Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyfuse Biomedical
What does Cyfuse Biomedical do?
Cyfuse Biomedical develops scaffold-free 3D bioprinting systems using its proprietary Kenzan Method to construct three-dimensional tissues from cell spheroids without scaffolds. Its core commercial offerings are the S-PIKE bio-3D printer (hardware), drug discovery support tools such as the Human 3D Mini Liver, and a pipeline of 3D cell products (artificial blood vessels, nerve conduits) for regenerative medicine applications.
Is Cyfuse Biomedical a public or private company?
Cyfuse Biomedical is a public company. It is classified as public and is currently operating.
When was Cyfuse Biomedical founded?
Cyfuse Biomedical was founded in 2010. It employs 11 to 50 people.
Where is Cyfuse Biomedical based?
Cyfuse Biomedical is headquartered in Tokyo, Japan, in the Asia region.
How does Cyfuse Biomedical make money?
Three revenue lines are on record. Bio-3D Printer Sales are the primary driver. The others are drug Discovery Support Tools and regenerative Medicine Products.
Who are Cyfuse Biomedical's main competitors?
Direct peers on record are CELLINK (BICO Group), Organovo, Aspect Biosystems, Poietis, InSphero and Emulate. Broad incumbents are Fujifilm and 3D Systems. Healios K.K. is listed as a regional player. Regemat 3D is listed as an emerging player.
Does Cyfuse Biomedical have an API?
No public API is recorded for Cyfuse Biomedical.
What industry is Cyfuse Biomedical in?
Cyfuse Biomedical's product category is 3D Bioprinting and Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 325414 and its SIC code is 2836.